chemical:semaglutide Kidney injuries on Ozempic Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
chemical:semaglutide Another GLP1 Generic launch: India's Dr Reddy's Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
company:hims Hims will sell generic Semaglutide in 2026 Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
company:novo-nordisk Novo Nordisk is introducing a higher dose of Wegovy Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
includes:study If GLP1 is so great, why don't people stick with it? Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
category:news A glowing endorsement of GLP1s by cardiologists Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
chemical:semaglutide After two months, Novo Nordisk and HIMS part ways Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
category:news Preserving muscle: GLP1s with Bimagrumab We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
company:novo-nordisk Novo Nordisk patent protections lapse in Canada Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
research Semaglutide vs Tirzepatide (Clinical trial) Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
malady:addiction GLP1s vs. Addiction, a quick review We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.
research STRIDE study: GLP1s vs peripheral artery disease (PAD) Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
company:novo-nordisk Novo Nordisk offers cheaper Wegovy Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
chemical:semaglutide Semaglutide removed from shortage list It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
category:news HIMS to offer Liraglutide after shortage rule changes HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?
chemical:semaglutide Semaglutide & Liraglutide continue to be effective Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.
category:side-effects Semaglutide's link to blinding disease (NAION) We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.
category:factsheet Patent expirations for GLP1 Receptor Agonists How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.
includes:study Are GLP1 side effects all the same? Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
chemical:semaglutide 24% Less kidney disease risk with Semaglutide (Ozempic) Can we trust research funded by Novo Nordisk which found a 24% decrease in kidney disease risk for people on Semaglutide (Ozempic)?
drug:ozempic Semaglutide (Ozempic) vs Tirzepatide (Mounjaro) Learn the major differences between Ozempic (Semaglutide) and Mounjaro (Tirzepatide)
